Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow coverage is tight, slightly below 100%. Pfizer's debt from recent deals adds financial pressure, though management prioritizes maintaining and growing the dividend. The dividend is considered moderately safe currently, but risks remain if free cash flow does not improve or if key product revenues decline further.
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining...
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
Roche Holding AG and Pfizer Inc. are aggressively developing new drugs targeting obesity and type 2 diabetes, aiming to capture growth in the GLP-1 market. Roche's enicepatide shows strong weight loss results in Phase 2 trials with a good safety prof...
In May, the Consumer Price Index (CPI) rose 4.2% year-over-year, matching expectations, with core CPI increasing 0.2%, slightly easing concerns about immediate Federal Reserve rate hikes. Supermicro announced plans to raise up to $7 billion through e...
